The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer

• Conditions: Rectal Cancer Stage III

• Registration Number: NCT04598984
• Lead Sponsor: Istanbul Training and Research Hospital

Brief Summary

It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-01
• Study First Submitted: 2020-10-09
• Study First Submitted QC: 2020-10-16
• Study First Posted: 2020-10-22
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-05
• Last Update Posted: 2022-08-08
• Primary Completion: 2022-12-30
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• All patients with locally advanced rectal cancer

Exclusion Criteria

• below 18 years old
• patients who did not received neoadjuvant therapyAll

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer	1 year	The Adiponectin, Adipsin, Leptin, Resistin levels will be measured with flow cytometric analysis.

Trial Locations

Locations (1)

Istanbul Training and Research Hospital; 🇹🇷 Istanbul, Turkey